Inventiva Names Andrew Obenshain as CEO, Replaces Co-Founder Frédéric Cren

Inventiva, a clinical-stage biopharmaceutical company, has appointed Andrew Obenshain as its new Chief Executive Officer. He will also join the Board of Directors, succeeding co-founder Frédéric Cren, who is stepping down. The leadership transition aims to support Inventiva's growth and development, particularly in preparing for potential commercialization in the US.

Inventiva, a clinical-stage biopharmaceutical company focused on developing oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), has appointed Andrew Obenshain as its new Chief Executive Officer (CEO). Obenshain will also join the Board of Directors, succeeding co-founder Frédéric Cren, who is stepping down. The leadership transition aims to support Inventiva's growth and development, particularly in preparing for potential commercialization in the US.

Obenshain's appointment comes at a pivotal time for Inventiva, as the company continues to advance its Phase 3 clinical trial, NATiV3, evaluating lanifibranor in patients with MASH. The trial, which completed enrollment in April 2025, is expected to provide top-line results in the second half of 2026 Inventiva reports its unaudited 2025 first-half financial results and provides a corporate update^[2].

The appointment of Obenshain, who has extensive experience in the biopharmaceutical industry, is seen as a strategic move to enhance Inventiva's leadership and prepare for the company's long-term objectives. Cren, who co-founded Inventiva and has been instrumental in its growth, will continue to serve as a member of the Board of Directors.

Inventiva's financial results for the first half of 2025 highlighted the company's progress in both clinical and financial aspects. The company reported revenues of €4.5 million, compared to none generated in the same period in 2024. The revenues were primarily driven by a $10 million milestone payment from Chia Tai Tianqing Pharmaceutical Group (CTTQ) and a $5 million credit note under the license agreement with CTTQ Inventiva reports its unaudited 2025 first-half financial results and provides a corporate update^[2].

The company's net loss for the first half of 2025 stood at €175.9 million, compared to €49.0 million for the same period in 2024. The net financial loss was mainly due to non-cash IFRS treatment of the accounting at the fair value, including €84.7 million related to derivative instruments in connection with the second tranche of the Structured Financing, and €17.9 million from warrants previously issued to the EIB Inventiva reports its unaudited 2025 first-half financial results and provides a corporate update^[2].

Inventiva's cash and cash equivalents amounted to €122.1 million as of June 30, 2025, compared to €96.6 million as of December 31, 2024. The company estimates that its current cash position, combined with the $10 million milestone payment received from CTTQ, should allow it to fund its operations until the end of the third quarter of 2026 Inventiva reports its unaudited 2025 first-half financial results and provides a corporate update^[2].

The leadership transition and the appointment of Obenshain are expected to bring new strategic insights and operational efficiencies to Inventiva, positioning the company for future growth and potential commercialization in the US.